Ionis Pharma

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ionis Pharma excels in Q4, eyes revenue growth and strategic expansion

Ionis Pharma's Q4 2022 performance reflects strong revenue growth, pipeline advancements, and strategic positioning for future success.
The company's focus on commercialization, R&D innovation, and financial discipline underscores its resilience and growth potential in the biopharmaceutical industry.
While facing challenges in operational costs and market dynamics, Ionis Pharma remains well-positioned to leverage opportunities in genetic medicines and revenue diversification.

Ionis Pharma reports strong Q1 earnings and outlines growth plans

Ionis Pharma's Q1 performance solid with revenue growth and strong cash position
Company's strengths lie in FDA approvals, positive study data, and pipeline progress
Challenges include rising expenses, competitive landscape, and pricing strategies
Opportunities seen in PV market, HAE program, and growth prospects in coming years

Ionis Pharma reports strong Q2 performance and prepares for launches

Ionis Pharma's Q2 2023 earnings call highlighted strong performance, with revenue growth, key milestones in pipeline advancements, and a solid financial position.
The company faces challenges in study readout timing, competitive landscape changes, and market competition but has opportunities for growth through successful enrollment and product launches.
Key strengths include successful collaborations, encouraging interim results for SPINRAZA, and preparations for upcoming product launches, positioning Ionis Pharma for future success.
Overall, Ionis Pharma remains focused on advancing its pipeline, meeting financial guidance, and leveraging opportunities for growth in the biopharmaceutical market.

Ionis Pharma reports strong Q3 performance and neurology pipeline advancements

Ionis Pharma's Q3 earnings call highlighted strong performance, strategic successes, and advancements in the neurology pipeline.
The company faces challenges in a competitive landscape but has strengths in partnerships, innovation, and pricing strategies.
Opportunities lie in upcoming data releases, potential treatment benefits, and market differentiation strategies.
Overall, Ionis Pharma remains focused on delivering value to patients and investors through its innovative therapeutics.

Ionis Pharma reports robust 2023 results and eyes growth opportunities

Ionis Pharma's strong financial performance in 2023 and projected revenue for 2024 reflect a promising outlook for the company's growth and commercialization efforts.
While facing challenges in patient eligibility and treatment optimization, Ionis Pharma's focus on pipeline advancement and strategic investments positions it well for future success.
The company's emphasis on neurological disease platforms, upcoming data readouts, and collaborations present significant opportunities for expansion and innovation.

Ionis Pharma reports robust Q1 performance and advances key treatments

Ionis Pharma's Q1 2024 performance reflects strong revenue growth and progress in key pipeline programs, positioning the company for future success and sustained positive cash flow.
With a focus on strategic investments, innovative treatments, and upcoming data presentations, Ionis demonstrates a commitment to driving growth and addressing unmet medical needs.
While facing challenges in managing expenses and securing regulatory approvals, Ionis Pharma remains well-positioned to capitalize on market opportunities and partnerships for continued development and commercial success.

Ionis Pharma reports solid Q2 earnings, eyes growth through innovation

Ionis Pharma's Q2 performance reflects steady revenue growth and positive feedback on recent launches and ongoing trials.
The company's strengths lie in its innovative therapies, strong clinical profile, and strategic focus on expanding the product portfolio.
Challenges include sustaining momentum in competitive markets and ensuring successful commercialization of upcoming products.
Opportunities exist in market expansion, new patient segments, partnerships for pipeline growth, and investments in next-gen technologies.

Ionis Pharma reports strong pipeline progress and commercial success

Ionis Pharma's Q3 earnings call highlighted positive pipeline developments, successful product launches, and sustained investment for growth.
While facing challenges in competitive positioning and data availability, Ionis Pharma remains focused on leveraging opportunities in patient engagement and market expansion.
Overall, Ionis Pharma's performance reflects a promising outlook with strong potential for future growth and market impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

-       Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B -       Phase 3 clinical study evaluating b epirovirsen as a monotherapy is anticipated to start in the first half of 2023 -       GSK to explore potential combination treatments to further reduce the global burden of chronic hepatitis B CARLSBAD, Calif. , June 25, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus (CHB).

Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™

Ionis (IONS), along with partner AstraZeneca, reports positive data from a phase III study, which is evaluating eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Ionis (IONS), AstraZeneca's Amyloidosis Drug Meets Study Goals

AstraZeneca

U.S.-listed shares of AstraZeneca AZN, +2.98% were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its primary endpoints in a Phase 3 clinical trial. AstraZeneca is developing eplontersen with Ionis Pharmaceuticals Inc. IONS, +5.54% ; shares in Ionis were up 5.1% on Tuesday.

AstraZeneca, Ionis plan to seek FDA approval for rare-disease therapy this year

-  Eplontersen showed statistically significant and clinically meaningful improvements in mNIS+7 and Norfolk QoL-DN -  Eplontersen demonstrated a favorable safety profile -  Ionis and AstraZeneca expect to file a New Drug Application this year CARLSBAD, Calif. , June 21, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from a 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

In the last 12 months, I count four Ionis programs that failed. This series of failures does not generate confidence.

Ionis Pharma: Too Many Programs Have Failed To Produce Confidence

The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.

Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag

CARLSBAD, Calif. , June 13, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease designation to ION582, an investigational antisense medicine for the treatment of Angelman syndrome, a rare neurogenetic disorder caused by the loss of function of the maternally inherited Ubiquitin Protein Ligase E3A (UBE3A) gene.

Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA

Exact Sciences

Kratos Defense & Security Solutions

UiPath

Trimble

Despite the recent selloff, these five Cathie Wood stocks are likely to bounce back thanks to their focus on impressive innovation. The post 5 Cathie Wood Stocks to Buy in June appeared first on InvestorPlace.

5 Cathie Wood Stocks to Buy in June

Twelve-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength and quality of life Tofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegeneration SOD1-ALS is a rare, progressive and fatal genetic form of the disease leading to loss of everyday functions and affecting approximately 2% of people with ALS CARLSBAD, Calif. , June 3, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Biogen today announced results from the Phase 3 VALOR study and its open-label extension (OLE) of tofersen, an investigational antisense medicine being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).

Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients

ARK Genomic Revolution Multi-Sector ETF

Burning Rock Biotech

Editas Medicine

Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?

Cathie Wood Is Selling Gene Editing Stocks. Here's Why.

CARLSBAD, Calif. , May 12, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022.

Ionis to present at RBC Capital Markets Global Healthcare Conference

Ionis (IONS) incurs a narrower-than-expected loss in Q1. Its sales also come ahead of estimates.

Ionis (IONS) Q1 Earnings & Sales Beat Estimates, Stock Rises

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2022 Earnings Conference Call May 4, 2022 11:30 AM ET Company Participants Brett Monia - Founder, CEO & Director Elizabeth Hougen - EVP, Finance & CFO Eugene Schneider - EVP & Chief Clinical Development Officer Eric Swayze - EVP, Research Onaiza Cadoret - EVP and Chief Product Strategy & Operations Officer Conference Call Participants Yanan Zhu - Wells Fargo Securities Brendan Smith - Cowen and Company Luca Issi - RBC Capital Markets Jessica Fye - JPMorgan Chase & Co. Mani Foroohar - SVB Leerink Gary Nachman - BMO Capital Markets I-Eh Jen - Laidlaw & Company Myles Minter - William Blair & Company Joseph Stringer - Needham & Company Alexander Thompson - Stifel, Nicolaus & Company Operator Good morning, and welcome to the Ionis Pharmaceuticals First Quarter 2022 Financial Results Conference Call. As a reminder, this call is being recorded.

Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q1 2022 Results - Earnings Call Transcript

On track to achieve 2022 financial guidance Webcast today, May 4, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif.

Ionis reports first quarter financial results and recent business achievements

CARLSBAD, Calif., May 2, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022.

Ionis to host 2022 virtual Annual Meeting of Stockholders

BioMarin Pharmaceutical

CRISPR Therapeutics

Intercept Pharma

Mirati Therapeutics

Novartis

Sarepta Therapeutics

Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of blockbuster products. The post 7 Potential Biotech Stocks Buyout Targets in 2022 appeared first on InvestorPlace.

7 Potential Biotech Stocks Buyout Targets in 2022

Webcast scheduled for Wednesday, May 4 at 11:30 a.m. Eastern Time CARLSBAD, Calif.

Ionis to hold first quarter 2022 financial results webcast

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is on a bullish streak that began three weeks ago. Last week, the brand reported success in research on a cholesterol drug that it is developing in partnership with AstraZeneca.

Hold Ionis Pharmaceuticals as the share price moved to find a $60 valuation

-  ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated -  ION449 demonstrated potential best-in-class efficacy profile for a self-administered subcutaneous monthly dose regimen -  Study findings warrant further clinical development of ION449 for patients with hypercholesterolemia at high cardiovascular risk CARLSBAD, Calif. , April 4, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its partner, AstraZeneca, today announced positive data from the ETESIAN Phase 2b study of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with hypercholesterolemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9).

Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session

Biogen

Biogen (BIIB) & partner Ionis (IONS) to terminate the development of their antisense ALS candidate, as the drug failed to show any clinical benefit in an early-stage study for C9orf72-associated ALS.

Biogen (BIIB), Ionis to End Early-Stage ALS Candidate Development

Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx) for C9orf72-associated amyotrophic lateral sclerosis (ALS). In this Phase 1 study, BIIB078 was generally well-tolerated.

Ionis-Biogen Partnered Amyotrophic Lateral Sclerosis Trial Disappoints

BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS) , did not show clinical benefit; clinical program will be discontinued Biogen and Ionis remain committed to their decade-long pursuit of advancing ALS research and developing therapies for all forms of this progressive and fatal neurodegenerative disease CAMBRIDGE, Mass. and CARLSBAD, Calif.

Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

Ionis Pharmaceuticals specializes in developing RNA-targeted therapeutics - one of the fastest-growing research areas in the biotech sector.

Ionis Pharmaceuticals: Finding Financial Value In Biotech Research

–  Treatment with donidalorsen in Phase 2 study significantly reduced angioedema attacks by 90% and provided improvement in quality of life –  Published findings demonstrate favorable safety and tolerability profile of donidalorsen in Phase 2 study –  Donidalorsen is one of Ionis' wholly owned medicines the company plans to commercialize CARLSBAD, Calif., March 16, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the publication of positive Phase 2 data for donidalorsen (formerly IONIS-PKK-LRx) in the New England Journal of Medicine (NEJM) available at NEJM.org.

Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine

Ionis has >$2 billion in cash, along with significant recurring revenue sources providing a solid foundation. It has had recurring difficulties in establishing increases to its product income.

News for Ionis Pharma Stock (IONS)